The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with the ...

Revolution Medicines, Inc. (NASDAQ:RVMD) has been making waves in the biotechnology sector with its innovative approach to ...

Merck (MRK) stock in focus as the company eyes 2025 launch of subcutaneous Keytruda amid a looming patent cliff for its ...

BBO-8520, an investigational oral agent, has been granted fast track designation from the FDA in previously treated KRAS G12C ...

(RTTNews) - Bicycle Therapeutics plc (BCYC), Monday announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) ...

Bicycle Therapeutics (BCYC) announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously ...

CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases ...

Updated overall survival data from KEYNOTE-564 showed adjuvant pembrolizumab benefits in clear cell renal cell carcinoma, but some patients remain unresponsive.

First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...